Artiva (ARTV) SVP Reports RSU Withholding of 2,384 Shares; Form 4 Filed

Rhea-AI Filing Summary

Raymon Heather, SVP, Research and Development of Artiva Biotherapeutics, Inc. (ARTV), reported two dispositions of common stock tied to restricted stock unit vesting tax-withholdings. On 05/15/2025 the issuer withheld 745 shares at an effective price of $2.13, leaving 42,605 shares beneficially owned. On 08/15/2025 an additional 1,639 shares were withheld at $2.75, leaving 40,966 shares.

The Form 4 was executed by an attorney-in-fact and discloses these routine withholding transactions to satisfy income tax obligations associated with RSU vesting. No derivatives, option exercises, or other types of transactions are reported, and the filing indicates direct ownership by the reporting person.

Positive

• Clear disclosure of withholding transactions tied to RSU vesting, showing compliance with Section 16 reporting
• Specific share counts and prices provided: 745 shares at $2.13 and 1,639 shares at $2.75, with remaining holdings stated

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine tax-withholding dispositions reduce insider share count; no change to company operations or control.

The reported transactions are standard withholding actions upon RSU vesting, not open-market sales. Total shares beneficially owned declined from 42,605 to 40,966 after the second withholding. Because these actions are employer-initiated to satisfy tax obligations, they do not represent a voluntary liquidity event by the officer and are unlikely to be material to ARTV's capitalization or investor valuation at the company level.

Corporate Governance Expert

TL;DR: Disclosure is timely and follows Section 16 reporting norms; no governance concerns evident.

The Form 4 lists the reporting person as an officer and indicates direct ownership. The explanation clarifies the nature of the dispositions as income tax withholdings tied to RSU vesting, which is a common practice. The filing was signed via attorney-in-fact, which is permissible. There are no red flags such as large voluntary sales, changes in control, or undisclosed derivative activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raymon Heather

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Research and Development

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2025		F		745(1)	D	$2.13	42,605	D
Common Stock	08/15/2025		F		1,639(1)	D	$2.75	40,966	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

	/s/ Neha Krishnamohan, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Raymon Heather report on the ARTV Form 4?

The filer reported two withholding dispositions: 745 shares on 05/15/2025 at $2.13 and 1,639 shares on 08/15/2025 at $2.75.

Why were shares disposed of according to the Form 4?

The Form 4 states the dispositions represent shares withheld by the issuer to satisfy income tax obligations associated with the vesting of restricted stock units.

How many ARTV shares does the reporting person own after these transactions?

Following the 05/15/2025 transaction the reporting person owned 42,605 shares, and after the 08/15/2025 transaction they owned 40,966 shares.

Was the Form 4 signed by the reporting person?

The filing was executed by an attorney-in-fact (/s/ Neha Krishnamohan) on 08/18/2025, as indicated on the form.

Did the Form 4 report any derivative or option transactions?

No. Table II shows no derivative securities; only non-derivative common stock withholding dispositions are reported.